Brokerages expect Juno Therapeutics, Inc. (NASDAQ:JUNO) to post earnings of ($0.74) per share for the current quarter, Zacks reports. Six analysts have provided estimates for Juno Therapeutics’ earnings. The highest EPS estimate is ($0.68) and the lowest is ($0.79). Juno Therapeutics reported earnings per share of ($0.65) in the same quarter last year, which indicates a negative year over year growth rate of 13.8%. The firm is scheduled to issue its next quarterly earnings results on Thursday, August 3rd.

On average, analysts expect that Juno Therapeutics will report full year earnings of ($3.00) per share for the current financial year, with EPS estimates ranging from ($3.14) to ($2.77). For the next fiscal year, analysts forecast that the business will post earnings of ($3.78) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Juno Therapeutics.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by $0.01. Juno Therapeutics had a negative return on equity of 24.57% and a negative net margin of 288.66%. The firm had revenue of $19.30 million during the quarter, compared to analysts’ expectations of $16 million. During the same period in the previous year, the company posted ($0.78) earnings per share. The company’s quarterly revenue was up 96.9% compared to the same quarter last year.

A number of research analysts recently issued reports on JUNO shares. Cowen and Company reiterated a “buy” rating and set a $36.00 price objective (down from $41.00) on shares of Juno Therapeutics in a research note on Thursday, March 30th. Vetr upgraded Juno Therapeutics from a “buy” rating to a “strong-buy” rating and set a $25.42 price objective for the company in a research note on Tuesday, March 21st. Leerink Swann reiterated an “outperform” rating on shares of Juno Therapeutics in a research note on Monday, June 12th. Citigroup Inc. cut their price objective on Juno Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, April 4th. Finally, Zacks Investment Research upgraded Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 price objective for the company in a research note on Tuesday, July 11th. One analyst has rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the stock. Juno Therapeutics currently has an average rating of “Buy” and a consensus price target of $30.81.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/0-74-eps-expected-for-juno-therapeutics-inc-juno-this-quarter/1445440.html.

In related news, CFO Steve Harr sold 8,750 shares of the stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $30.00, for a total transaction of $262,500.00. Following the sale, the chief financial officer now owns 736,189 shares in the company, valued at approximately $22,085,670. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Anthony B. Evnin purchased 9,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The shares were bought at an average price of $24.40 per share, for a total transaction of $219,600.00. Following the acquisition, the director now directly owns 66,301 shares in the company, valued at approximately $1,617,744.40. The disclosure for this purchase can be found here. Insiders have sold a total of 41,500 shares of company stock worth $1,230,360 over the last ninety days. Insiders own 15.26% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in JUNO. Baillie Gifford & Co. raised its stake in Juno Therapeutics by 1.2% in the first quarter. Baillie Gifford & Co. now owns 11,197,863 shares of the biopharmaceutical company’s stock valued at $248,481,000 after buying an additional 135,908 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Juno Therapeutics by 5.2% in the first quarter. Vanguard Group Inc. now owns 6,153,812 shares of the biopharmaceutical company’s stock valued at $136,553,000 after buying an additional 303,912 shares during the period. BlackRock Inc. increased its position in shares of Juno Therapeutics by 31,399.7% in the first quarter. BlackRock Inc. now owns 4,183,793 shares of the biopharmaceutical company’s stock valued at $92,838,000 after buying an additional 4,170,511 shares during the period. BB Biotech AG increased its position in shares of Juno Therapeutics by 16.8% in the first quarter. BB Biotech AG now owns 2,185,000 shares of the biopharmaceutical company’s stock valued at $48,485,000 after buying an additional 315,000 shares during the period. Finally, First Trust Advisors LP increased its position in shares of Juno Therapeutics by 47.1% in the first quarter. First Trust Advisors LP now owns 1,377,667 shares of the biopharmaceutical company’s stock valued at $30,570,000 after buying an additional 440,984 shares during the period. Institutional investors own 64.51% of the company’s stock.

Shares of Juno Therapeutics (NASDAQ JUNO) traded up 1.76% during midday trading on Monday, hitting $27.74. 564,903 shares of the stock were exchanged. Juno Therapeutics has a 52-week low of $17.52 and a 52-week high of $35.04. The firm’s 50 day moving average price is $24.94 and its 200-day moving average price is $22.57. The stock’s market cap is $2.89 billion.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Get a free copy of the Zacks research report on Juno Therapeutics (JUNO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.